Cycrimine

Summary

Cycrimine (CHEMBL1201227) is an approved small-molecule antiparkinson drug.

At a glance

• Status: Approved (max clinical phase 4)
• Modality: Small molecule
• Chemistry: 287.4 Da · C19H29NO

Identifiers

Drug identity and classification

Field	Value
ChEMBL ID	CHEMBL1201227
Name	Cycrimine
Type	Small molecule
Max phase	4
FDA approved	no
PubChem CID	2911
ChEBI	CHEBI:59692
Molecular formula	C19H29NO
Molecular weight	287.4
InChIKey	SWRUZBWLEWHWRI-UHFFFAOYSA-N

SMILES: C1CCN(CC1)CCC(C2CCCC2)(C3=CC=CC=C3)O

IUPAC name: 1-cyclopentyl-1-phenyl-3-piperidin-1-ylpropan-1-ol

ChEBI definition: A member of the class of piperidines that is 3-(piperidin-1-yl)propan-1-ol in which one of the hydrogen atoms at the 1-position is substituted by cyclopentyl, and the other is substituted by phenyl. A central anticholinergic, it is used as its hydrochloride salt in the management and treatment of Parkinson’s disease.

Pharmacological roles (ChEBI): antiparkinson drug, muscarinic antagonist, antidyskinesia agent.

Also known as: Cicrimina, Cycrimine, COMPOUND-08958, CYCRIMINE

Parent form; salt/anhydrous children: CHEMBL1200828

Patent coverage: 188 distinct patent families (549 SureChEMBL compound mentions), from 1 matched compound structure(s). Mentions count patents naming the compound (not distinct inventions), so promiscuous / reference molecules inflate the mention figure — families are the dedup metric.

Targets

Targets

No target linkage available.

Bioactivity

No ChEMBL bioactivity rows at pChembl ≥ 5 (expected for biologics / antibodies).

Target pathways

No target-pathway data for this drug (no mapped target genes).

Indications & clinical

Indications

0 indication records carry no mapped disease name (EFO/MeSH-only); none shown.

Clinical trials

Total trials: 0.

Clinical evidence (CIViC)

No CIViC predictive evidence (expected for non-precision-medicine drugs).

Pharmacology

Pharmacogenomics

No CPIC/DPWG dosing guideline or drug-level clinical/variant annotations in PharmGKB for this molecule.

Related molecules

Related molecules

No competitor molecules sharing a primary target (ChEMBL phase ≥2 or PubChem drug-class).